PROfound Puts Lynparza On Track For Prostate Cancer Indication
Executive Summary
AstraZeneca and Merck & Co said their PARP inhibitor Lynparza has become the first to show positive Phase III trial data in metastatic castration-resistant prostate cancer, putting pressure on rival Clovis’s Rubraca.
You may also be interested in...
AstraZeneca Q3 Preview: Oncology Portfolio Keeps Growing
AstraZeneca, which analysts said had an 'exceptional' second quarter, is expected to have also kept that momentum up in the third quarter.
Lynparza Poised To Bring Targeted Therapy To Prostate Cancer
The detailed data from PROfound showed the PARP inhibitor doubled the time to radiographic progression-free survival in men with homologous recombination repair (HRRm) gene mutations.
AZ Pushes Further Ahead In PARP Race With Lynparza/Avastin Combo
The PAOLA-1 study has shown the benefit of Lynparza for ovarian cancer patients regardless of tumor mutation status which should firm up the drug's dominance in the PARP inhibitor space.